ARM1 is primarily used in research settings as a selective inhibitor of the ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) tyrosine kinases. It demonstrates potent activity in blocking signaling pathways involved in cell proliferation and survival, particularly in cancer cells harboring ALK or ROS1 gene rearrangements. Due to its ability to cross the blood-brain barrier, ARM1 is valuable in studying central nervous system involvement in ALK-positive cancers, such as non-small cell lung cancer. It is also employed in preclinical models to evaluate tumor response, resistance mechanisms, and combination therapies with other anticancer agents. Its high specificity and pharmacokinetic profile make it a useful tool compound in oncology drug development.